News
TransCon CNP demonstrated significantly higher annualized growth velocity, the primary endpoint, compared to placebo – ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback